Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib Maintenance in Small Cell Lung Cancer
NCT00066313Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2003
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in small cell lung cancer (SCLC), sponsored by Sanofi. Started May 2003; status: completed.
02
Drugs
vandetanib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00066313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066313.